Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]
SEC Accession No. 0001144204-17-014555
Filing Date
2017-03-14
Accepted
2017-03-14 17:26:08
Documents
57
Period of Report
2016-09-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q/A v459885_10qa.htm 10-Q/A 431610
2 EXHIBIT 31.1 v459885_ex31-1.htm EX-31.1 10759
3 EXHIBIT 31.2 v459885_ex31-2.htm EX-31.2 10814
4 EXHIBIT 32.1 v459885_ex32-1.htm EX-32.1 3782
5 EXHIBIT 32.2 v459885_ex32-2.htm EX-32.2 3798
  Complete submission text file 0001144204-17-014555.txt   3845324

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT rasp-20160930.xml EX-101.INS 957939
7 XBRL TAXONOMY EXTENSION SCHEMA rasp-20160930.xsd EX-101.SCH 32454
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE rasp-20160930_cal.xml EX-101.CAL 20437
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE rasp-20160930_def.xml EX-101.DEF 195683
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE rasp-20160930_lab.xml EX-101.LAB 234077
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rasp-20160930_pre.xml EX-101.PRE 238869
Mailing Address 420 LEXINGTON AVENUE 25TH FLOOR NEW YORK NY 10170
Business Address 420 LEXINGTON AVENUE 25TH FLOOR NEW YORK NY 10170 212-398-4627
Rasna Therapeutics Inc. (Filer) CIK: 0001582249 (see all company filings)

EIN.: 392080103 | State of Incorp.: NV | Fiscal Year End: 0630
Type: 10-Q/A | Act: 34 | File No.: 333-191083 | Film No.: 17689029
SIC: 2834 Pharmaceutical Preparations